USE OF CA-19-9 IN THE EARLY DETECTION OF RECURRENCES IN COLORECTAL-CANCER - COMPARISON WITH CEA

被引：46

作者：

FILELLA, X

MOLINA, R

PIQUE, JM

GARCIAVALDECASAS, JC

GRAU, JJ

NOVELL, F

ASTUDILLO, E

DELACY, A

DANIELS, M

BALLESTA, AM

机构：

[1] HOSP CLIN BARCELONA,DEPT GASTROENTEROL,BARCELONA,SPAIN

[2] HOSP CLIN BARCELONA,DEPT SURG,BARCELONA,SPAIN

[3] HOSP CLIN BARCELONA,DEPT ONCOL,BARCELONA,SPAIN

来源：

TUMOR BIOLOGY | 1994年 / 15卷 / 01期

关键词：

CA; 19-9; CEA; CANCER-ASSOCIATED ANTIGENS; COLORECTAL CANCER; FOLLOW-UP;

D O I：

10.1159/000217867

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The serum levels of CA 19-9 were determined in the follow-up of 370 patients with colorectal cancer and compared with CEA. An increase in CA 19-9 preceded clinical diagnosis of recurrence in 25% of 72 patients. The mean time between the rise in CA 19-9 and clinical diagnosis of relapse was 3.7 months (median 3). Sensitivity of CA 19-9 in the early diagnosis of recurrence was much lower than that obtained for CEA (75%). Only 1 patient had elevated CA 19-9 levels and normal CEA.

引用

页码：1 / 6

页数：6

共 50 条

[41] CA 19-9 As a Marker in Addition to CEA to Monitor Colorectal Cancer
Stiksma, Jolanda
Grootendorst, Diana C.
van der Linden, Peter Willem G.
CLINICAL COLORECTAL CANCER, 2014, 13 (04) : 239 - 244
[42] THE NEW TUMOR-MARKER CA-72-4 IN COMPARISON WITH CA-19-9 AND CEA IN GASTROINTESTINAL-DISEASES
HEPTNER, G
DOMSCHKE, S
SCHNEIDER, MU
DOMSCHKE, W
NUC COMPACT-EUROPEAN-AMERICAN COMMUNICATIONS IN NUCLEAR MEDICINE, 1988, 19 (04): : 132 - 134
[43] THE NEW TUMOR-MARKER CA-72-4 IN COMPARISON WITH CA-19-9 AND CEA IN GASTROINTESTINAL-DISEASE
HEPTNER, G
DOMSCHKE, S
SCHNEIDER, MU
DOMSCHKE, W
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1988, 26 (09): : 598 - 598
[44] BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer.
Kasi, Pashtoon Murtaza
Kamatham, Saivaishnavi
Colibaseanu, Dorin
Shahjehan, Faisal
Merchea, Amit
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[45] SERIAL LEVELS OF MONOCLONAL-ANTIBODY CA-19-9 IN COLONIC-CANCER AND BENIGN LIVER-DISEASE - COMPARISON WITH CEA
NOVIS, BH
GLUCK, E
THOMAS, P
STEELE, G
ZAMCHECK, N
GASTROENTEROLOGY, 1985, 88 (05) : 1519 - 1519
[46] CLINICAL COMPARISON OF FDG-PET AND CEA-IMMUNOSCINTIGRAPHY FOR DETECTION OF COLORECTAL-CANCER
BARES, R
DOHMEN, BM
FASS, J
KAISER, HJ
ALTEHOEFER, C
KLEVER, P
SCHUMPELICK, V
BUELL, U
JOURNAL OF NUCLEAR MEDICINE, 1994, 35 (05) : P108 - P108
[47] COMPARISON OF PLASMA CEA AND ALPHA-1-ACID GLYCOPROTEIN IN THE DETECTION OF COLORECTAL-CANCER
CHU, C
WANG, HP
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1979, 72 (03): : 333 - 333
[48] THE TUMOR-MARKERS CA-125, CA-19-9, CA-15-3 AND CEA IN OVARIAN-CANCER
HOFFMANN, L
MULLERHAGEN, S
FRANZ, G
KLAPDOR, R
DIETEL, M
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1987, 242 (1-4) : 371 - 372
[49] CA-19-9 (MONOSIALOGANGLIOSIDE) IN PRIMARY LUNG-CANCER - A COMPARISON WITH CARCINOEMBRYONIC ANTIGEN
VINDIMIAN, M
LAFITTE, JJ
WATTRE, P
BIOMEDICINE & PHARMACOTHERAPY, 1987, 41 (04) : 191 - 195
[50] EARLY DETECTION OF COLORECTAL-CANCER IN WORKERS
BERGAZ, AO
MEDICINA CLINICA, 1993, 101 (11): : 437 - 438

← 1 2 3 4 5 →